

HPV vaccines gain traction in India, though cost keeps reach limited
Subscribe to enjoy similar stories. Bengaluru/Mumbai: India’s HPV vaccine market is seeing a clear revival after years of low uptake, with digital health platforms and private healthcare providers reporting a sharp rise in demand amid growing awareness of cervical cancer prevention. On PharmEasy, a digital-first diagnostics and pharmacy company backed by Prosus and Temasek, HPV vaccines now account for nearly 25% of total vaccine sales, making it one of the fastest-growing segments within its preventive healthcare portfolio.
The rise reflects growing consumer awareness and easier access through digital channels, particularly in urban India. “HPV vaccination has seen substantial growth on PharmEasy, driven by rising awareness about preventive healthcare and the convenience we offer," said Gaurav Verma, head (B2C) at PharmEasy. Features such as at-home vaccination, flexible scheduling and free administration have helped reduce friction for consumers, enabling families to prioritise the vaccine, he added.
HPV, or human papillomavirus, is linked to several types of cancer, most commonly cervical. India’s HPV vaccine market was worth ₹91 crore as of January 2026, on a moving annual total basis, according to pharma intelligence platform Pharmarack. US-based drugmaker Merck's Gardasil dominated the market with ₹70 crore sales.
Read on livemint.com